Highest-materiality recent filing
Teladoc names Michael Grasher CFO; base salary $550K, $500K sign-on bonus
Michael Grasher appointed CFO effective Aug 31, 2026; prior CFO of IFG Companies, Fortegra, AMERISAFE.
Teladoc director David B. Snow Jr. to retire from board effective Sept 30, 2026
David B. Snow Jr. notified Teladoc on Aug 10, 2026 of his retirement from the Board.
Teladoc Health appoints former Verisk president Mark Anquillare to board
Mark V. Anquillare appointed to Teladoc Health board effective August 3, 2026.
Teladoc Q2 revenue down 4% to $606.9M; BetterHelp segment revenue falls 12%
Net loss of $38.9M ($0.21 per share) vs $32.7M loss a year ago; adjusted EBITDA $65.7M, down 5%.
Teladoc Health holds 2026 annual meeting; all director nominees elected
All eight director nominees elected; David B. Snow, Jr. received 67.4M for (12.9M against).
Teladoc Health Q1 2026 Revenue Falls 2% to $613.8M, Net Loss Narrows to $63.8M
First Quarter 2026 revenue of $613.8 million, down 2% year-over-year
Teladoc Health appoints Susan Salka, ex-AMN Healthcare CEO, to its board
Susan Salka appointed to Teladoc board effective March 30, 2026; will serve on audit and compensation committees.
Teladoc Q4 revenue flat at $642M, net loss narrows; FY2026 revenue guidance $2.47-2.587B
Q4 2025 revenue $642.3M (flat YoY); net loss $25.1M vs $48.4M loss; adjusted EBITDA $83.8M (+12% YoY).
Teladoc appoints Michael Smith, former Voya Financial CFO, to board
Appointment of Michael Smith to board effective Feb 18, 2026; board size temporarily expanded to 10.
Director Thomas G. McKinley to retire from Teladoc Health board effective Feb 20, 2026
Thomas G. McKinley, a director since 2009, notified Teladoc of his retirement effective Feb 20, 2026.
Teladoc director J. Eric Evans to retire at 2026 Annual Meeting, not standing for reelection
J. Eric Evans notified Teladoc on Dec 11, 2025 of intention not to stand for reelection at the 2026 Annual Meeting.
Teladoc Health increases inducement plan share reserve by 1.78M shares to 7.28M
Board approved amendment effective Dec 9, 2025 to increase share reserve by 1,780,000 shares to total 7,280,000 shares under 2023 Inducement Plan.
Teladoc Q3 revenue down 2% to $626.4M; net loss widens to $49.5M; adj. EBITDA falls 16%
Revenue $626.4M (-2% YoY); net loss $49.5M ($0.28 per share) vs. $33.3M loss a year ago.
Teladoc Health CFO Mala Murthy resigns; preliminary Q3 revenue $626.4M, adj EBITDA $69.9M
CFO Mala Murthy to resign effective Nov 21, 2025; interim finance leaders reporting to CEO.
Net loss of $32.7M ($0.19 per share), improved from $837.7M loss in Q2 2024 which included $790M goodwill impairment.
Teladoc Health enters $300M senior secured revolving credit facility
Five-year $300M senior secured revolver with JPMorgan Chase as administrative agent; no immediate borrowings planned.
Shareholders approved amendment to 2023 Incentive Award Plan, increasing authorized shares by 6,850,000.
Teladoc Q1 revenue down 3% to $629M; net loss widens on $59M goodwill impairment; acquires UpLift
Revenue $629.4M (-3% YoY); net loss $93M ($0.53/sh) includes $59.1M goodwill impairment.
Teladoc Health Q4 revenue $640.5M (-3% YoY); full-year net loss $1.0B on $790M goodwill impairment
Q4 revenue $640.5M (-3% YoY); full-year revenue $2,569.6M (-1% YoY).
Teladoc Q3 revenue $640.5M (-3% YoY), net loss narrows to $0.19 EPS; BetterHelp revenue down 10%
Revenue $640.5M (-3% YoY); net loss $33.3M ($0.19 per share) vs $57.1M loss last year.
Teladoc Health COO Michael Waters resigns effective Dec 31, 2024
COO Michael Waters resigns with good reason due to change in executive reporting structure.
Teladoc Health appoints Joseph Catapano as SVP and Chief Accounting Officer
Joseph Catapano joined Teladoc as SVP and Chief Accounting Officer effective Sept 9, 2024.
Q2 revenue $642.4M (-2% YoY); net loss $837.7M ($4.92/sh) includes $790M goodwill impairment for BetterHelp.
Teladoc Health terminates President Laizer Kornwasser without cause, effective July 1, 2024
Laizer Kornwasser, President of Enterprise Growth and Global Markets, terminated without cause; effective July 1, 2024.
Teladoc Health names Chuck Divita as CEO effective June 10, 2024
Charles Divita appointed CEO and board member; Mala Murthy returns to CFO role.
Teladoc Health reports 2024 annual meeting voting; all director nominees elected
All eight director nominees elected; votes for ranged from 74.9M to 88.2M.
Teladoc Health Q1 revenue +3% to $646.1M; adjusted EBITDA +20% to $63.1M
Revenue $646.1M (+3% YoY); net loss $81.9M ($0.49 EPS) vs $69.2M loss in Q1 2023.
Teladoc Health CAO Richard Napolitano resigns, effective May 3, 2024
Napolitano leaves to pursue another career, no disagreement with company.
Teladoc CEO Jason Gorevic departs; CFO Mala Murthy named acting CEO
Jason Gorevic departs immediately; Board retains search firm for permanent successor.
Teladoc Q4 2023 revenue $660.5M, adj. EBITDA up 22% to $114.4M; guides FY2024 revenue $2.64-2.74B
Q4 revenue $660.5M (+4% YoY); Full year revenue $2,602.4M (+8% YoY).
Teladoc Health Chief Innovation Officer Claus Jensen resigns; receives $743,750 separation
Claus Jensen resigns as Chief Innovation Officer effective December 1, 2023.
Teladoc Q3 revenue up 8% to $660.2M; adjusted EBITDA surges 73% to $88.8M
Net loss narrowed to $57.1M ($0.35/sh) from $73.5M ($0.45/sh) a year ago; adjusted EBITDA $88.8M.
Teladoc Health appoints Surgery Partners CEO Eric Evans to board of directors
Eric Evans, CEO of Surgery Partners (SGRY), appointed to Teladoc Health board effective September 20, 2023.
Teladoc Health Q2 revenue $652M (+10% YoY); adj EBITDA $72.2M beats outlook
Revenue $652.4M (+10% YoY); Integrated Care $360.1M (+5%), BetterHelp $292.4M (+18%).
Teladoc Health shareholders approve new incentive plan and ESPP amendment; severance plan for execs
Shareholders approved the 2023 Incentive Award Plan, authorizing 8,250,000 shares for future equity grants.
Teladoc Q1 revenue $629M (+11% YoY); net loss $0.42/sh; guides Q2 rev $635-660M
Revenue $629.2M (+11% YoY); Integrated Care $350M (+5%), BetterHelp $279M (+21%).
Teladoc Health Q4 revenue up 15% to $637.7M; net loss of $3.81B on $3.77B goodwill impairment
Full-year 2022 revenue $2.41B (+18% YoY); net loss $13.66B ($84.60/share) driven by $13.4B non-cash goodwill impairment.
Teladoc Health cuts workforce 6% (~300 roles), expects $17M in 2023 restructuring charges
Layoffs affect ~300 non-clinician employees, ~6% of workforce; office space reductions in certain markets.
Teladoc pre-announces Q4 revenue $633-640M; FY22 revenue $2.403-2.410B
FY2022 total revenue guided $2.403B-$2.410B, including ~$1B from BetterHelp.
Teladoc Health appoints Laizer Kornwasser as President, Enterprise Growth & Global Markets
Laizer Kornwasser appointed President, Enterprise Growth & Global Markets effective Oct 24, 2022.
Teladoc Health Q3 revenue up 17% to $611.4M; net loss narrows to $73.5M
Q3 revenue $611.4M (+17% YoY); net loss $73.5M ($0.45/sh) vs $84.3M loss prior year.
Teladoc Health reports Q2 revenue $592M (+18% YoY) but net loss $3.1B on $3.0B goodwill impairment
Revenue $592.4M (+18% YoY); net loss per share $19.22, mainly from $3.0B non-cash goodwill impairment.
Teladoc Health appoints Mike Waters as COO effective July 25, 2022
Waters joins from Providence (EVP, Ambulatory Care Network) to oversee operations, member services, and supply chain.
Teladoc shareholders approve 15% net long ownership special meeting right
Certificate amendment enabling 15% net long holders to call special meetings approved and filed.
Teladoc Q1 net loss $6.67B on $6.6B goodwill impairment; cuts 2022 guidance
Q1 revenue $565.4M (+25% YoY); net loss $6.67B due to $6.6B non-cash goodwill impairment ($41.11/sh).
Teladoc Q4 revenue $554M (+45% YoY); 2022 guidance $2.55-2.65B
Q4 revenue $554.2M (+45% YoY); full year 2021 revenue $2.03B (+86% YoY).
Teladoc Health pre-announces FY2021 revenue of approximately $2.03B
Preliminary total revenue for year ended Dec 31, 2021 is about $2,030 million.
Investor day held on November 18, 2021 with slide presentation furnished as Exhibit 99.1.
Teladoc Q3 revenue up 81% YoY to $522M; updates FY2021 revenue outlook to $2.015-$2.025B
Net loss of $84.3M ($0.53 per share) vs $35.9M loss ($0.43) in Q3 2020.
Teladoc Health COO David Sides resigns effective Sept 21; reaffirms 2021 guidance
COO David Sides resigns effective September 21, 2021, to pursue another employment opportunity.
Effective August 31, 2026, Teladoc Health, Inc. (the “Company”) hired Michael Grasher as its Chief Financial Officer.
On September 27, 2024, Michael Waters, Chief Operating Officer of Teladoc Health, Inc. (the “Company”), resigned with good reason under his executive employment agreement with the Company in connection with a change in the Company's executive reporting structure.
Effective September 9, 2024, Joseph Catapano joined Teladoc Health, Inc. (the “Company”) as its Senior Vice President and Chief Accounting Officer.
On June 28, 2024, Teladoc Health, Inc. (the “Company”) terminated without cause the employment of Laizer Kornwasser, President, Enterprise Growth and Global Markets, in connection with a change in the Company's executive reporting structure, effective July 1, 2024.
appointed Mr. Divita as a director of the Company.
Charles Divita, III joined Teladoc Health, Inc. (the “Company”) as its Chief Executive Officer.
Mala Murthy stepped down as acting Chief Executive Officer of the Company and will remain the Company's Chief Financial Officer.
On April 8, 2024, Mr. Richard J. Napolitano, Chief Accounting Officer (Principal Accounting Officer) of Teladoc Health, Inc. (the “Company”) informed the Company of his decision to resign, effective May 3, 2024, to pursue another career opportunity.
Upon Mr. Napolitano’s departure and until such time as a permanent replacement is named, Mr. James L. Cave, Vice President, Corporate Controller will assume his duties and responsibilities on an interim basis.
Teladoc Health announced the appointment of Mala Murthy to the position of acting Chief Executive Officer of the Company, effective immediately.
replacing Jason Gorevic, who will also depart from the Board of Directors of the Company as required by his employment agreement.
On November 8, 2023, Claus T. Jensen, PhD resigned as Chief Innovation Officer of Teladoc Health, Inc. (the “Company”), effective December 1, 2023 (the “Separation Date”).
Max materiality 0.90 · Median 0.60 · Most common event earnings